YF-S0
A viral vector SARS-CoV-2 candidate vaccine.
General information
YF-S0 is a yellow fever 17D-vector experimental SARS-CoV-2 vaccine with modified prefusion form Spike protein serving as an immunogen (Sanchez-Felipe et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
Spike protein Viral vector Animal model Mixed substance |
STAT2-/- hamsters and BALB/c mice (safety assessment); Syrian hamsters; Ifnar-/- AG129 mice; cynomolgus macaques | 42.78 | The virus-vectored vaccine is functional and produces SARS-CoV-2 Spike protein (non-cleavable), which is properly N-glycosylated. Vaccinated hamsters rapidly produced high titres of Spike-specific neutralizing IgGs and quickly reduced viral loads after an aggressive challenge. Lungs of vaccinated hamsters were protected from SARS-CoV-2-induced damage and the immunization prevented systemic hyperinflammation. Strong humoral and cellular responses were observed also in a murine model and neutralizing antibodies were induced in cynomolgus macaques. No indication of disease enhancement or antibody-dependent enhancement was noted. |
Dec/01/2020 |
AI-suggested references
| Link | Publication date |
|---|---|
|
Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
|
Nov/22/2021 |
